GlassScriptPhysician profile
Rhonda C Navarro
NPI 1144990839
$6,616.42
in general payments reported to CMS, 2019-2025
28 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $2,186 · 2023: $2,161 · 2024: $1,878 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,113 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,113.28 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,267.91 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $714.35 | 2022-2024 | Xifaxan, Trulance, Plenvu |
| Nestle Healthcare Nutrition INC. | $547.55 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $433.90 | 2021-2024 | Entyvio, Gattex |
| Genzyme Corporation | $335.74 | 2022-2024 | |
| Janssen Biotech, INC. | $322.59 | 2023-2024 | Stelara, Tremfya |
| Qol Medical, LLC | $318.82 | 2021-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $258.45 | 2024-2025 | Resmetirom, Rezdiffra |
| Celgene Corporation | $216.70 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $166.67 | 2024 | Omvoh |
| Gilead Sciences, INC. | $131.79 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $131.29 | 2022-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $97.06 | 2022-2024 | Linzess |
| Ardelyx, INC. | $95.75 | 2022-2023 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $88.70 | 2022-2024 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $83.00 | 2022-2023 | Injectafer |
| Braintree Laboratories, INC. | $59.94 | 2022-2023 | Sutab |
| Merck Sharp & Dohme LLC | $55.34 | 2022 | |
| Organon LLC | $53.94 | 2023-2024 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.85 | 2023-2024 | Cyltezo |
| Pfizer INC. | $33.55 | 2024 | |
| Glaxosmithkline, LLC. | $28.88 | 2024 | Trelegy Ellipta |
| Redhill Biopharma INC. | $28.57 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.34 | 2025 | Bylvay |
| Alexion Pharmaceuticals, INC. | $21.73 | 2021 | |
| Aimmune Therapeutics, INC. | $19.45 | 2024 | |
| Phathom Pharmaceuticals, INC. | $17.43 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Navarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.